Close

Leerink Notes Positive Celgene (CELG) CFO Meeting

Go back to Leerink Notes Positive Celgene (CELG) CFO Meeting

Oppenheimer Starts Celgene (CELG) at Outperform

November 28, 2016 4:05 PM EST

Oppenheimer initiates coverage on Celgene (NASDAQ: CELG) with a Outperform rating and a price target of $141.00.

Analyst Leah Rush Cann commented, "We are initiating coverage of Celgene Corporation, a high-quality biotechnology company with exciting potential new products, with an Outperform... More